Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 17Colorectal Neoplasms 3Postoperative Complications 2Anastomotic Leak 2Transfusion Reaction 1Recurrence 1Rectal Cancer Stage T1-T2 1Pathologic Complete Response 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1Colitis, Ulcerative 1Colitis, Ischemic 1Coitus 1

Interventions

Carboplatin 7Trastuzumab 6Docetaxel 5pembrolizumab 4Paclitaxel 4Oxaliplatin 4Fluorouracil 4Cytarabine 4Cyclophosphamide 4Azacitidine 4pertuzumab 3Radiotherapy 3Observation 3Neoadjuvant Therapy 3Epirubicin 3Endoscopy 3Cisplatin 3Chemoradiotherapy 3Capecitabine 3venetoclax 2toripalimab 2sargramostim 2olaparib 2durvalumab 2cc-486 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Pemetrexed 2Monatide (IMS 3015) 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Complete Response × Proctectomy × Clear all
NCT03601689 2018-07-26

Predictive Factors of Disease-free Survival After Complete Pathological Response to Neoadjuvant Radiotherapy in Rectal Adenocarcinoma

Moroccan Society of Surgery

Completed
84 enrolled
Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡